Core Insights - Nexalin Technology Inc. (NASDAQ:NXL) experienced a significant stock price increase of 69.47%, reaching $1.59, with a trading volume of 167.9 million shares compared to the average of 972.2 thousand shares [1][7]. Clinical Data and Findings - The company published positive clinical data indicating that its proprietary 15 milliamp (mA) Gen-2 Nexalin DIFS technology improves cognitive performance and enhances brain network connectivity in patients with mild Alzheimer's disease (AD) [2]. - Patients using Nexalin's Gen-2 SYNC 40-Hz DIFS device showed significant improvements in Mini-Mental State Examination (MMSE) scores and Montreal Cognitive Assessment (MoCA) scores compared to baseline, with statistical significance (P = .001 and .03, respectively) [3]. - Resting-state functional MRI (fMRI) demonstrated enhanced functional connectivity (FC) between the hippocampus and critical cortical regions, which are essential for memory and executive function, with significant increases observed across broader cognitive networks [4]. Correlation and Safety - Increased connectivity between the hippocampus and middle cingulate gyrus correlated with improvements on the Boston Naming Test (r = 0.65, FDR-adjusted P = .008), indicating a link between brain network modulation and functional outcomes [5]. - No adverse events were reported during the treatment period, highlighting the safety and tolerability of Nexalin's DIFS technology [5]. Regulatory Approvals and Strategy - Nexalin's Gen-2 SYNC 15 mA DIFS device is already approved in China for treating depression and insomnia, and it has approvals in Brazil and Oman for anxiety, depression, and insomnia [6]. - The new Alzheimer's data supports the company's strategy to expand treatment indications with various international regulatory agencies, including the FDA in the United States [6].